Friday 6 November 2026
Export EXEL’s income statement to Excel — free account
Exelixis, Inc.
EXEL Healthcare Biotechnology
Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +22.2%
- Free cash flow
- −4.83%
Quarter to September 2026, against a year earlier
69.55
0.84
+1.22%
Follow EXEL
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
7 | 7 | 7 | 7 |
+8 more TTM periods Free account |
| 44.32% | 44.39% | 40.99% | 35.53% | ||
| 33.17% | 33.28% | 30.69% | 27.02% | ||
ROIC |
66.59% | 60.45% | 50.53% | 49.46% | |
Return on Tangible Assets |
88.78% | 87.68% | 89.31% | 68.85% | |
Average Days of Receivables |
48.02 | 48.28 | 50.54 | 45.14 | |
Free Cash Flow per Share |
4.64 | 4.62 | 3.50 | 3.11 | |
Free Cash Flow |
1,144.49 | 1,158.19 | 905.17 | 844.34 | |
Capital Expenditures |
(28.57) | (25.24) | (19.51) | (39.93) | |
| Other line items | |||||
Cash ROIC |
41.99% | 43.17% | 33.36% | 26.22% | |
Accounts Receivable Turnover |
7.82 | 7.93 | 7.78 | 8.40 | |
Accounts Payable Turnover |
3.32 | 2.64 | 2.52 | 2.47 | |
Inventory Turnover |
3.26 | 3.28 | 3.28 | 3.80 | |
Average Days of Payables |
120.59 | 166.43 | 104.36 | 129.19 | |
Days of Inventory on Hand |
116.83 | 122.41 | 114.95 | 94.57 | |
Tax Rate |
(0.17) | (0.17) | (0.17) | (0.17) | |
Research and Development Expense of Revenue |
33.43% | 33.84% | 34.21% | 35.56% | |
Selling, General and Administrative Expense of Revenue |
22.62% | 21.92% | 21.94% | 22.36% | |
Share Based Compensation of Revenue |
4.42% | 4.62% | 4.89% | 4.87% | |
Operating CF/Net income |
1.33 | 1.38 | 1.11 | 1.13 | |
Depreciation/Fixed assets |
0.32 | 0.31 | 0.30 | 0.29 | |
Capex/Depreciation |
(1.03) | (0.89) | (0.68) | (1.37) | |
Revenue per Share |
10.12 | 9.71 | 9.20 | 8.54 | |
Operating CF per Share |
4.75 | 4.72 | 3.58 | 3.26 | |
Capex per Share |
(0.12) | (0.10) | (0.08) | (0.15) | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.02 |
Columns are period end dates · fundamentals updated 5 Nov 2026